UroGen Pharma Ltd. announced the appointment of Dan Wildman to its Board of Directors, effective immediately. Dan Wildman, Chairman of the Board of Progenerative Medical Inc., a 40-year veteran of the medical device industry, and Strategic Advisor to several medical device and pharmaceutical companies, has agreed to join UroGen's board, effective immediately. Dan spent most of his career with Johnson & Johnson, where he most recently led the Digital Surgery Strategy Initiative that developed an integrated strategy for robotic surgery for the Company.

Prior to Digital Surgery, Dan led DuPuy Synthes Spine, the second-largest surgery business in the world where he engineered and executed an integrated turn-around plan for the Company. Before DuPuy Synthes, Dan served as Worldwide President of Ethicon Biosurgery, a division of Ethicon Inc., where he focused on the development and commercialization of biomaterial, biologic and combination products that changed the standard of care for intraoperative hemostasis. In his role, Dan transitioned the company from Advanced Wound Care to Biosurgery through a combination of acquisitions, divestitures, and internal capability development.

The Biosurgery business at Ethicon continues to be one of the fastest-growing companies in J&J's portfolio. Before J&J, Dan spent 10 years with Boston Scientific Corporation in a variety of sales, marketing, operations and strategic planning roles. Dan received a Bachelor of Arts degree in Economics from St.

Lawrence University in NY.